Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Nov 21, 2014
Tekmira Provides Key Highlights of Analyst and Investor Day in New York

Nov 17, 2014
Tekmira Announces Licensing and Collaboration Agreement With Dicerna

View all »Events & Presentations

Nov 21, 2014 at 9:00 AM ET
Tekmira Pharmaceuticals Corporation Analyst Day

Nov 19, 2014
Stifel Healthcare Conference